A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2002
12/12/2002	US20020188101 Conjugated peptide nucleic acids having enhanced cellular uptake
12/12/2002	US20020188028 Anti-infective compositions, methods and systems for treating disordered tissue
12/12/2002	US20020188019 Use of hydroxyflavanones for masking bitter taste
12/12/2002	US20020188013 Composition for treatment of malignant tumors
12/12/2002	US20020187993 Bifunctional energy-reversible acyl-compositions
12/12/2002	US20020187941 Pregabalin lactose conjugates
12/12/2002	US20020187933 Cardiovascular disorders; regeneration of heart tissue
12/12/2002	US20020187744 Ventilating device for ventilating through a ridge
12/12/2002	US20020187199 Unimolecular polymeric micelles with an ionizable inner core
12/12/2002	US20020187198 Site specific ligation of proteins to synthetic particles
12/12/2002	US20020187197 Templating of solid particles by polymer multilayers
12/12/2002	US20020187196 Capsules capsules actic-co-glycolic copolymer to which a citric ester plasticizer has been incorporated and which contain a peptide drug within them.
12/12/2002	US20020187191 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
12/12/2002	US20020187190 Polymer film compositions for capsules
12/12/2002	US20020187189 Proliposomal drug delivery system
12/12/2002	US20020187186 Pharmaceutical tablets
12/12/2002	US20020187185 Gelatin substitute
12/12/2002	US20020187181 System for delivering cosmetics and pharmaceuticals
12/12/2002	US20020187171 Composition for solubilizing salicylic acid
12/12/2002	US20020187169 Kavalactone compositions
12/12/2002	US20020187165 Composition for female sexual arousal
12/12/2002	US20020187156 Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
12/12/2002	US20020187153 Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
12/12/2002	US20020187149 Activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptible carrier.
12/12/2002	US20020187141 Composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent; determination whether the failure of traditional chemotherapy is due to multidrug resistant tumor cells
12/12/2002	US20020187134 Prebiotic and probiotic compositions and methods for their use in gut-based therapies
12/12/2002	US20020187131 Conjugating an antigen to a molecule targeted to an endocytic receptor on the dendritic cell, such as DEC-205. The molecule targeted may be a natural ligand to the receptor or an antibody thereto.
12/12/2002	US20020187105 Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
12/12/2002	US20020187068 Method of inactivating pathogens
12/12/2002	DE10127134A1 Production of injection molded shaped articles, especially for retarded drug release, by blending (meth)acrylate copolymer with plasticizer and other additives, degassing and molding
12/12/2002	DE10126501A1 Composition used for detaching abnormal keratin material e.g. warts or fungally damage nails, comprises mixture of urea, film former and water or aqueous alcohol
12/12/2002	DE10126158A1 Mixtures of alpha-hydroxy-omega-alkoxy- and alpha-omega-dialkoxy-polyoxyalkylene containing little or no dihydroxy-polyoxyalkylene, used for coupling and modification of proteins and other bioactive molecules
12/12/2002	CA2452865A1 Conditioned cell culture media and uses thereof
12/12/2002	CA2450009A1 Method and apparatus for treating tumors using low strength electric fields
12/12/2002	CA2449873A1 Cell penetrating therapeutic agents
12/12/2002	CA2449842A1 Zinc containing compositions for anti-viral use
12/12/2002	CA2449712A1 Method for reducing muscle fatigue through administration of adenosine triphosphate
12/12/2002	CA2449686A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002	CA2449426A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002	CA2449320A1 Mixtures of growth hormone drug-oligomer conjugates compromising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002	CA2449103A1 Topical compositions for veterinary uses
12/12/2002	CA2448861A1 Methods and formulations for enhancing the dissolution of a solid material in liquid
12/12/2002	CA2448858A1 Lipid-polymer-conjugates compositions
12/12/2002	CA2448856A1 Lipid-polymer-conjugates
12/12/2002	CA2448665A1 Sustained-release analgesic compounds
12/12/2002	CA2447695A1 Modified antibodies to prostate-specific membrane antigen and uses thereof
12/12/2002	CA2447111A1 Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds
12/12/2002	CA2446929A1 Orally administering parathyroid hormone and calcitonin
12/11/2002	EP1264837A1 Conjugation-stabilized polypeptide compositions
12/11/2002	EP1264612A1 Method for nasal application of a medicinal substance
12/11/2002	EP1264602A2 Pharmaceutical composition comprising high tapped density fumed silica
12/11/2002	EP1264600A1 Immune enhancement compositions and use thereof
12/11/2002	EP1264595A1 Use of tocopherol derivatives for stabilizing nano-sized emulsion particles containing lecithin and their external application to the skin
12/11/2002	EP1264181A1 Carriers coated with polysaccharides, their preparation and use
12/11/2002	EP1263948A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/11/2002	EP1263818A1 Cosmetic agent
12/11/2002	EP1263802A1 Hydrogel biomedical articles
12/11/2002	EP1263801A1 Tissue bulking and coating compositions
12/11/2002	EP1263793A1 Single phase gels for the prevention of adhesions
12/11/2002	EP1263776A2 Peptides targeting specifically tumor-derived endothelial cells
12/11/2002	EP1263761A2 Compounds for pdt
12/11/2002	EP1263721A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
12/11/2002	EP1263474A1 A method of sensitising endothelial cells to prodrugs
12/11/2002	EP1263473A2 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
12/11/2002	EP1263472A2 Modification of biopolymers for improved drug delivery
12/11/2002	EP1263471A2 Antimicrobial compounds and formulations
12/11/2002	EP1263470A1 METHOD FOR PRODUCING A COENZYME Q10 / $g(g)-CYCLODEXTRIN COMPLEX
12/11/2002	EP1263469A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues
12/11/2002	EP1263468A1 Formulation solubilizing water-insoluble agents and preparation method thereof
12/11/2002	EP1263467A1 Improved paste formulations
12/11/2002	EP1263463A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cells
12/11/2002	EP1263461A1 Adenovirus formulations
12/11/2002	EP1263457A2 Hiv immune adjuvant therapy
12/11/2002	EP1263456A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"
12/11/2002	EP1263455A2 Uses of bombesin receptor 3
12/11/2002	EP1263454A2 Methods for enhancing the bioavailability of a drug
12/11/2002	EP1263453A2 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
12/11/2002	EP1263441A2 Acetylsalicylic acid solutions
12/11/2002	EP1263439A2 Sustained release ranolazine formulations
12/11/2002	EP1263433A2 Glycogen phosphorylase inhibitor
12/11/2002	EP1263426A1 Preparations for the non-traumatic excision of a nail
12/11/2002	EP1263422A1 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd)
12/11/2002	EP1263417A2 Stabilised oversaturated transdermal therapeutical matrix systems
12/11/2002	EP1263416A2 Compressed microparticles for dry injection
12/11/2002	EP1263414A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors
12/11/2002	EP1263413A1 Method of preparing solid dispersions
12/11/2002	EP1263411A2 Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
12/11/2002	EP1263410A1 Urogenital or anorectal transmucosal vaccine delivery system
12/11/2002	EP1263409A1 Orally administered controlled delivery system for once daily administration of ciprofloxacin
12/11/2002	EP1263392A1 Clear water-in-oil emulsions
12/11/2002	EP1263363A1 Colored visco-elastic composition
12/11/2002	EP1263347A2 System for the controlled delivery of an active material to a dental site
12/11/2002	EP1263327A1 Biocompatible material composition adaptable to diverse therapeutic indications
12/11/2002	EP1263325A1 Embolic agents visible under ultrasound
12/11/2002	EP1263297A1 Diabetic nutritionals
12/11/2002	EP1124535B1 Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
12/11/2002	EP1077683B1 Antidepressant therapy
12/11/2002	EP1063969B1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect
12/11/2002	EP1023072B1 Analgesic compositions comprising a cholecystokinin and an opioid
12/11/2002	EP0888384B1 Fusion polypeptide for modifying interactions between proteins

1 ... 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 ... 1712